Table 2. Case-level analyses on the associations between potential covariates and Chlamydia trachomatis-positive samples (positivity) and load from days 23–51 after treatment.
| Positivity, Days 23–51 | Load, Days 23–51 | |
| OR 95% CI a | Difference log load | |
| (IFU/ml) 95% CI a | ||
| Time post treatment (per day) | 1.004 (1.00;1.01) # | 0.01 (0.001;0.02) * |
| Anorectal case | 1.16 (0.92;1.45) | 0.19 (−0.22;0.61) |
| Age <23 years | 1.06 (0.90;1.24) | −0.05 (−0.41;0.32) |
| History of Ct diagnosis | 0.96 (0.81;1.14) | 0.14 (−0.39;0.69) |
| Pre-treatment load >75% percentile b | 1.01 (0.83;1.23) | Anorectal: 0.99 (0.04;2.02)c * |
| Cervicovaginal: −0.16 (−0.75;0.42)c | ||
| Current symptoms d , e | 1.02 (0.89;1.16) | −0.20 (−0.47;0.07) |
| Pre-treatment symptoms d , f | 0.94 (0.80;1.11) | −0.31 (−0.71; −0.09) |
| Current menstruation f | 0.96 (0.86;1.07) | 0.03 (−0.33;0.40) |
| Sexual re-exposure risk: unsafe sex | 0.99 (0.69;1.09) | −0.07 (−0.45;0.32) |
| with a new partner/unknown behavior |
Abbreviations: OR: Odds Ratio; CI: Confidence Interval; IFU/ml: Inclusion-forming units per milliliter.
#: P = 0.06,
*P<0.05; tested using generalized estimating equations (positivity) or mixed models (load).
estimates adjusted for potential confounding by sexual re-exposure risk, anatomic site, and repeated measurements; in models with bacterial load as outcome, anatomic site was included as an effect-modifier as the interaction-term was statistically significant.
>159 IFU/ml for anorectal cases and >1299 IFU/ml for cervicovaginal cases.
presented separately for anatomic sites due to significant interactions between pre-treatment load and site (P = 0.008).
dysuria; irregular menstruation; lower abdominal pain; pain during intercourse; vaginal discharge.
anal discharge; anal blood loss during/after intercourse; anal pain during/after intercourse.
only evaluated for cervicovaginal cases.